ARTICLE | BODY SHAPING |
SLIMMING CREAM TO TREAT LOCALISED SUBCUTANEOUS ADYPOSITIES
EVALUATION OF A NEW COSMECEUTICAL
Adele Sparavigna, Regina Vesnaver, Anna Cenni, Marco Oliva discuss the efficacy of a cosmeceutical slimming cream to treat adiposities of the waist and hips
ABSTRACT
ADELE SPARAVIGNA, Derming, Clinical Research and Bioengineering Institute, Milan, Italy; REGINA VESNAVER, Oikos Srl, Milan, Italy; ANNA CENNI, Società Italo Britannica L. Manetti – H. Roberts & C. per Azioni, Florence, Italy; MARCO OLIVA (pictured), Società Italo Britannica L. Manetti – H. Roberts & C. per Azioni, Florence, Italy
email: acenni@manetti-roberts.
boltongroup.it
The purpose of this double-blind randomised study was to evaluate the efficacy and tolerability of a new cosmeceutical formulation to reduce light-to-moderate localised adiposities symmetrically distributed on the waist and hips. The study was conducted in accordance with the ethical principles derived from the Declaration of Helsinki and Good Clinical Practices. After obtaining a properly detailed informed consent, a group of 110 female volunteers (aged 30–55 years; mean age 48 years) were instructed to blindly apply two apparently
KEYWORDS localised adiposities, transcutaneous chemical lipolysis
16 ❚
higher percentage of body fat compared with men. Female pattern fat distribution mainly involves lower body areas, and the hips and thighs in particular (Figure 1). This peculiar fat distribution is considered an important component of a normally occurring physiologic behaviour, aiming to provide an adequate caloric supply in cases of pregnancy and subsequent lactation. Excessively evident localised adiposities may generate variable degrees of social distress and psychological
G July/August 2012 |
prime-journal.com ENDER-RELATED
identical topical products, rubbing them twice every day on selected localised adiposities for a total duration of 4 weeks. The active formulation and placebo cream were blindly assigned to all study subjects. Objective evaluation was carried out at four fixed time intervals. Clinical assessment consisted of standardised measurements of anatomical circumferences; standardised ultrasound-assisted measurements of subcutaneous adipose tissue; and standardised plicometry. All anatomical regions treated using the cosmeceutical formulation showed a significant reduction
LOCALISED
adiposities affect approximately 85% of the post-adolescent female population in industrialised countries1
. Fat
distribution differs greatly between the genders. Women generally have a
of localised adiposities compared with placebo. No adverse events and/ or complications were observed in both active and placebo treated areas. Subjective evaluation was performed using self-assessment questionnaires. All study subjects considered intrinsic cosmeceutical characteristics generally good, without significant differences between formulations. Subjective perception of cosmeceutical effectiveness was undoubtedly better for active formulation compared with placebo.
embarrassment, potentially interfering with an otherwise normal quality of life (QOL), as well as highlighting previously undetected metabolic disturbances. A variety of invasive and non-invasive strategies have been proposed to reduce and control the evolution of excessively evident localised adiposities with variable degrees of success. Present trends favour combinations of different treatment options offering safer and more effective solutions to properly address this widespread cosmetic problem. Topical treatments might have a role in reducing unwanted localised adiposities, as well as in maintaining positive clinical results obtained after different medico-surgical procedures. None of these treatments should nevertheless be considered as a substitute for a properly balanced diet associated with regular physical exercise.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84